AASM tells sleep clinicians tirzepatide is a tool, not a cure, for sleep apnea

The American Academy of Sleep Medicine published guidance for sleep clinicians on September 3, 2025, on prescribing tirzepatide for obstructive sleep apnea. The message to clinicians: tirzepatide is a tool, not a cure, it works best alongside lifestyle change and continued OSA therapy, and CPAP should not be discontinued without proper reassessment ^[1].

The guidance appeared in Montage, an AASM publication for sleep professionals, and covers patient selection, monitoring, contraindications and insurance hurdles. It follows the FDA's December 2023 approval of tirzepatide (Zepbound) as the first medication indicated for moderate-to-severe OSA in adults who also have obesity ^[1].

What the trial data showed

The approval rested on the SURMOUNT-OSA trial, which compared tirzepatide with placebo in adults who had moderate-to-severe OSA, defined as an apnea-hypopnea index of 15 or higher, plus obesity. The study included both CPAP users and people not using CPAP, and all participants received lifestyle counseling on healthy eating and physical activity ^[1].

According to the AASM, tirzepatide produced clinically meaningful improvements in AHI and in patient-reported sleep quality. It also significantly improved cardiovascular risk factors tied to both OSA and obesity. Its safety profile was consistent with other incretin-based therapies, and dropout rates due to side effects were low ^[1].

The article states that the goal of tirzepatide therapy is not to replace traditional OSA treatments like CPAP, but to serve as an additional tool that targets what it calls the root cause in many patients: excess weight ^[1].

Patient education and long-term use

The AASM advised clinicians that patients may arrive with high expectations. It recommends clear messaging that tirzepatide is a tool, not a cure, and that it works best when combined with lifestyle interventions and continued OSA therapy, with CPAP not discontinued without proper reassessment ^[1].

Patients should also understand this may be long-term therapy, much like blood pressure medication, the guidance says. It cites the SURMOUNT-4 trial, published in JAMA, which emphasized the need to continue pharmacotherapy to prevent weight regain and preserve improvements in cardiometabolic risk factors. Stopping tirzepatide may affect any reductions in AHI and improvements in OSA severity seen while on the drug ^[1].

On safety, tirzepatide is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or a known allergy to the medication. The guidance says clinicians should use caution in patients with gastroparesis, pancreatitis, gallbladder disease, renal failure or eating disorders, and in those with uncontrolled diabetes, depression or suicidal ideation, or who are pregnant or planning pregnancy ^[1]. No labs are required by the FDA label, though many experts recommend a baseline metabolic panel, especially for patients with chronic kidney disease ^[1].

Board certification in obesity medicine is not required to prescribe tirzepatide, the AASM notes, but prescribers should understand side effects, titration and nutrition, and it recommends partnering with a registered dietitian or behavioral specialist ^[1].

Why it matters for patients

For people with OSA and obesity, this is the first drug option aimed at the condition itself rather than only its symptoms. But the guidance makes clear that it is not a replacement for existing therapy, and that stopping CPAP on your own is not advised without a reassessment ^[1].

The practical barrier is coverage. Eli Lilly lists Zepbound at $1,086.37 per fill, though out-of-pocket cost depends on the insurance plan ^[1]. Some Medicare plans with drug coverage may cover Zepbound for OSA but not for weight loss alone, and the Centers for Medicare & Medicaid Services is considering expanding coverage of anti-obesity medications beginning in 2026 ^[1]. Many insurers require prior authorization ^[1]. CVS Health announced Zepbound would be excluded from its covered drug list as of July 1, 2025 ^[1].

The AASM also warned that compounded versions sold online or through direct-to-consumer platforms are not FDA-regulated and may not contain the correct active ingredient, and said clinicians should counsel patients to avoid them ^[1].

What happens next

CMS's consideration of broader anti-obesity medication coverage beginning in 2026 is pending ^[1]. Whether the AASM will turn this guidance into a formal clinical practice guideline has not been reported.